Oricell Therapeutics Holdings Ltd closed a $110 million pre-IPO round to expand its global footprint and advance its lead candidate, a GPC3-targeted autologous CAR T therapy for liver cancer to ...

Realta Life Sciences Inc. raised an additional $40 million in the final tranche of its series A investment, bringing the ...

There are new data to chew over in the ongoing controversy about obesity being diagnosed as a disease from a study tracking ...

Armed with a fully subscribed $80 million series D round, Life Biosciences Inc. is making progress with its lead candidate, ER-100, which is in phase I trials testing its theory on reversing the ...

Avelos Therapeutics Inc. has divulged new sulfur or selenium-containing compounds acting as DNA polymerase θ (POLθ; POLQ) inhibitors potentially useful for the treatment of cancer.

Invivyd Inc. has announced the discovery and advancement of VMS-063, a novel monoclonal antibody candidate for the treatment ...

Nyrada Pty Ltd. has synthesized new short transient receptor potential channel 6 (TRPC6) and 7 (TRPC7) antagonists potentially useful for the treatment of cancer.

Researchers from the Cyprus Institute of Neurology and Genetics and collaborators report the development of a gene silencing therapy for Charcot-Marie-Tooth type 1A.

Gilead Sciences Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera ...

Replimune Group Inc. received another complete response letter (CRL) from the U.S. FDA for immunotherapy vusolimogene ...

Co. Ltd. have identified new macrocyclic GTPase KRAS inhibitors potentially useful for the treatment of cancer.